Skip to main content

Inhibition of IKK complex


Dual inhibition of IκB kinase 1/2 for cancer therapy


The NF-κB signaling pathway plays a pivotal role in a broad range of cellular processes including cell proliferation and survival and is tightly linked to diseases such as cancer.

Bilder & Videos


The invention provides com-positions comprising IKK1 and IKK2 antagonists for use in medical treatments of proliferative disorders, in particular for the treatment of cancer. Most preferred in context of the invention is a gene editing approach for a targeted simultaneous knockout of the genes of IKK1 and IKK2 in a cell associated with the proliferative disorder. 

Simultaneous CRISPR/Cas9-mediated knockout of IKBKA (IKK1) and IKBKB (IKK2) resulted in cells highly sensitized for programmed cell death (apoptotic/necroptotic) after exposure to tumor necrosis factor (TNF)-α. This effect was not observable in single knockouts for either IKK1 or IKK2. Targeting of IKK1 and IKK2 simultaneously, preferably on the genome level, therefore opens up new therapeutic avenues to tackle proliferative disorders such as cancer. Hence, the present methods and compositions provide a means for the selective induction of apoptosis in cells associated with a proliferative disorder, such as tumor cells.


  • Novel gene therapy for cancer
  • Novel screening strategy
  • Therapy option for drug-resistant cancers 


Novel gene therapy and a novel drug screening concept are offered for licensing. In case of interest we are pleased to inform you about the patent status.

PROvendis GmbH

Prof. Dr. Frank Entschladen
+49.208 94105-20
Schloßstr. 11-15
45468 Mülheim an der Ruhr




inhibitorische kappa B Kinase, Krebs, Gentherapie, IKK, inhibitory kappa B kinase, cancer, gene therapy, CRISPR/CAS

Angebot Anbieter-Website

Kontakt | Geschäftsstelle

TransferAllianz e. V.
Christiane Bach-Kaienburg

c/o PROvendis GmbH
Schloßstr. 11-15
D-45468 Mülheim an der Ruhr